Part VI: Summary of the risk management plan

Summary of risk management plan for Bleomycin 15000 IU Powder for solution for injection/ infusion

This is a summary of the risk management plan (RMP) for Bleomycin 15000 IU Powder for solution for injection/ infusion. The RMP details important risks of Bleomycin 15000 IU Powder for solution for injection/ infusion, how these risks can be minimised, and how more information will be obtained about Bleomycin 15000 IU Powder for solution for injection/ infusion's risks and uncertainties (missing information).

Bleomycin 15000 IU Powder for solution for injection/ infusion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Bleomycin 15000 IU Powder for solution for injection/ infusion should be used.

Important new concerns or changes to the current ones will be included in updates of Bleomycin 15000 IU Powder for solution for injection/ infusion's RMP.

I. The medicine and what it is used for

Bleomycin can be used in the treatment of

- Squamous cell carcinoma (SCC) of the head and neck, cervix and external genitalia
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma of intermediate and high malignancy in adults
- Testicular carcinoma (seminoma and non-seminoma)
- Intrapleural therapy of malignant pleural effusions.

Bleomycin can be used as a monotherapy, but is usually combined with other cytostatics and/or radiation therapy.

It contains bleomycin as the active substance and it may be administered intravenously, intramuscularly, intra-arterially, subcutaneously or by intrapleural instillation. Local injection directly into the tumour may occasionally be indicated.

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorization Holder.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Bleomycin 15000 IU Powder for solution for injection/ infusion together with measures to minimise such risks and the proposed studies for learning more about Bleomycin 15000 IU Powder for solution for injection/ infusion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed during signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Bleomycin 15000 IU Powder for solution for injection/ infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Bleomycin 15000 IU Powder for solution for injection/ infusion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorization Holder.

Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Bleomycin 15000 IU Powder for solution for injection/ infusion.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Bleomycin 15000 IU Powder for solution for injection/ infusion.

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorization Holder.